Uncategorized
Milestone payment improves 2012 revenue, net loss at Nicox
Nicox recorded revenue of €7.6 million in 2012 after recording no revenue in 2011, according to a company news release. The revenue increase was largely related to a $10 million milestone payment from Bausch + Lomb, which opted to continue developing latanoprostene bunod, a glaucoma drug candidate. As a result, there was a net loss of €10.2 million in 2012 compared with a net loss of €16.6 million in 2011.